These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 7466030

  • 21. Hormonal therapy for metastatic prostate cancer.
    Small EJ.
    West J Med; 1994 Mar; 160(3):253-4. PubMed ID: 8191763
    [No Abstract] [Full Text] [Related]

  • 22. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
    Ragavan N, Singh PB, Martin FL, Baird AD.
    Eur Urol; 2009 Feb; 55(2):e43-4. PubMed ID: 18771846
    [No Abstract] [Full Text] [Related]

  • 23. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
    Ogan K, Berger M, Ball R.
    J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
    [No Abstract] [Full Text] [Related]

  • 24. [Complete androgen blockage in the treatment of metastatic prostate cancer].
    Matzkin H, Braf Z.
    Harefuah; 1994 Mar 01; 126(5):260-3. PubMed ID: 8188104
    [No Abstract] [Full Text] [Related]

  • 25. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S, Simon JM, Mazeron JJ.
    Bull Cancer; 2009 Mar 01; 96(3):261-70. PubMed ID: 19318304
    [Abstract] [Full Text] [Related]

  • 26. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma.
    Bazinet M, Zheng W, Bégin LR, Aprikian AG, Karakiewicz PI, Elhilali MM.
    Urology; 1997 May 01; 49(5):721-5. PubMed ID: 9145977
    [Abstract] [Full Text] [Related]

  • 27. Stage D1 prostate cancer--delayed androgen deprivation.
    Richie JP.
    Urology; 1997 Dec 01; 50(6):838-9. PubMed ID: 9426710
    [No Abstract] [Full Text] [Related]

  • 28. Prostate cancer-producing granulocyte colony-stimulating factor.
    Matsuoka Y, Arai G, Okada Y, Aida J.
    Urol Int; 2009 Dec 01; 82(1):113-5. PubMed ID: 19172109
    [Abstract] [Full Text] [Related]

  • 29. [Prostatic carcinoma].
    Weingärtner K, Gerharz EW, Riedmiller H.
    Dtsch Med Wochenschr; 1994 Feb 18; 119(7):235-43. PubMed ID: 7508847
    [No Abstract] [Full Text] [Related]

  • 30. Rationale for suppression of adrenal steroidogenesis in advanced prostatic cancer.
    Blankenstein MA, Bakker GH.
    Prog Clin Biol Res; 1985 Feb 18; 185A():161-85. PubMed ID: 4034575
    [No Abstract] [Full Text] [Related]

  • 31. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar 18; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 32. [RS3PE syndrome as a first manifestation of prostatic carcinoma].
    Ramos Soria F, Doménech Santasusana M, Guasch Jordan I, López Borràs E, Busquet Solé N.
    An Med Interna; 2003 Apr 18; 20(4):217-8. PubMed ID: 12768842
    [No Abstract] [Full Text] [Related]

  • 33. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS, Ludgate CM, Wilson AG, Alexander AS.
    Can J Urol; 2000 Oct 18; 7(5):1099-103. PubMed ID: 11114872
    [Abstract] [Full Text] [Related]

  • 34. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F, Lorenzo Patiño MJ, Díaz Bermúdez J, Duarte Novo J, Alvarez Castelo L, Chantada Abal V, Sánchez Rodríguez J, González Martín M.
    Arch Esp Urol; 1997 May 18; 50(4):355-63. PubMed ID: 9313044
    [Abstract] [Full Text] [Related]

  • 35. Where is radiotherapy for stage C prostate cancer headed?
    Hanks GE.
    Contemp Urol; 1994 Mar 18; 6(3):11-4. PubMed ID: 10146746
    [No Abstract] [Full Text] [Related]

  • 36. Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?
    Akaza H.
    Can J Urol; 2005 Feb 18; 12 Suppl 1():77-80. PubMed ID: 15780172
    [Abstract] [Full Text] [Related]

  • 37. [Castration of prostate cancer patients and cognition].
    Portin R, Koskinen A, Helenius H, Nurmi M, Salminen E.
    Duodecim; 2005 Feb 18; 121(16):1784-5. PubMed ID: 16268226
    [No Abstract] [Full Text] [Related]

  • 38. [Combined androgen blockade for prostate cancer].
    Shimazui T.
    Nihon Rinsho; 2016 May 20; 74 Suppl 3():578-83. PubMed ID: 27344797
    [No Abstract] [Full Text] [Related]

  • 39. [A case of prostate cancer with invasion to the middle ureter].
    Matsuo T, Hayashida Y, Takehara K, Tsuda S, Furukawa M, Iwasaki S.
    Hinyokika Kiyo; 2004 Jan 20; 50(1):61-3. PubMed ID: 15032020
    [Abstract] [Full Text] [Related]

  • 40. [Results of the treatment of prostatic cancer (author's transl)].
    Takayasu H, Ogawa A, Koiso K, Komine Y, Ishii Y.
    Nihon Hinyokika Gakkai Zasshi; 1978 Apr 20; 69(4):426-35. PubMed ID: 671900
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.